Bernhard Heinrich

2.4k total citations
36 papers, 630 citations indexed

About

Bernhard Heinrich is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bernhard Heinrich has authored 36 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Bernhard Heinrich's work include Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (11 papers) and Brain Metastases and Treatment (6 papers). Bernhard Heinrich is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (11 papers) and Brain Metastases and Treatment (6 papers). Bernhard Heinrich collaborates with scholars based in Germany, United States and United Kingdom. Bernhard Heinrich's co-authors include Volker Heinemann, Hans‐Joachim Stemmler, Michael Untch, S. Kahlert, J. Wanders, Martin Grießhammer, Markus Bangerter, Jaap Verweij, Steffen Kahlert and Andreas Schneeweiß and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Bernhard Heinrich

33 papers receiving 612 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernhard Heinrich Germany 14 439 187 160 129 66 36 630
Meghan Nechrebecki United States 3 404 0.9× 238 1.3× 226 1.4× 116 0.9× 51 0.8× 4 542
Neha Luthar United States 6 292 0.7× 139 0.7× 236 1.5× 75 0.6× 64 1.0× 6 525
Konstantinos Tsaparikos United States 7 515 1.2× 225 1.2× 230 1.4× 86 0.7× 45 0.7× 11 682
Vincent A. Pollack United States 9 423 1.0× 228 1.2× 219 1.4× 128 1.0× 57 0.9× 12 660
Elvire Pons‐Tostivint France 13 468 1.1× 351 1.9× 238 1.5× 66 0.5× 134 2.0× 47 764
A. D. Colevas United States 10 391 0.9× 113 0.6× 355 2.2× 32 0.2× 55 0.8× 24 652
Daniel P. Petro United States 11 243 0.6× 194 1.0× 188 1.2× 31 0.2× 49 0.7× 21 428
Ulla Kasten-Pisula Germany 15 389 0.9× 300 1.6× 538 3.4× 145 1.1× 197 3.0× 17 883
J. Mendelsohn United States 10 373 0.8× 164 0.9× 266 1.7× 251 1.9× 77 1.2× 19 686
U Vogt Germany 13 320 0.7× 108 0.6× 293 1.8× 110 0.9× 114 1.7× 32 580

Countries citing papers authored by Bernhard Heinrich

Since Specialization
Citations

This map shows the geographic impact of Bernhard Heinrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard Heinrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard Heinrich more than expected).

Fields of papers citing papers by Bernhard Heinrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard Heinrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard Heinrich. The network helps show where Bernhard Heinrich may publish in the future.

Co-authorship network of co-authors of Bernhard Heinrich

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard Heinrich. A scholar is included among the top collaborators of Bernhard Heinrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard Heinrich. Bernhard Heinrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Koschmieder, Steffen, Susanne Isfort, Clemens Schulte, et al.. (2023). Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Annals of Hematology. 102(12). 3383–3399. 6 indexed citations
3.
Schaller, Tina, N. Patrick Mayr, Sebastian Dintner, et al.. (2023). Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT). Cancer Reports. 7(1). e1916–e1916. 5 indexed citations
4.
Whelan, Brendan, et al.. (2020). Magnetic modeling of actively shielded rotating MRI magnets in the presence of environmental steel. Physics in Medicine and Biology. 66(4). 45004–45004. 1 indexed citations
5.
Heinrich, Bernhard, et al.. (2015). Chemotherapie: besser als ihr Ruf. MMW - Fortschritte der Medizin. 157(14). 39–44.
6.
Wiechno, Paweł, Bradley G. Somer, Begoña Mellado, et al.. (2013). A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer. European Urology. 65(3). 516–520. 50 indexed citations
7.
Goldstein, LJ, Bernhard Heinrich, Salomon M. Stemmer, et al.. (2012). Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC).. Cancer Research. 72(24_Supplement). P5–20. 4 indexed citations
8.
Heinemann, Volker, Dorit Di Gioia, Ursula Vehling‐Kaiser, et al.. (2010). A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Annals of Oncology. 22(3). 603–608. 19 indexed citations
9.
Heinrich, Bernhard. (2010). Die Kehrseite der Medaille. MMW - Fortschritte der Medizin. 152(41). 36–36. 1 indexed citations
10.
11.
Stemmler, Hans‐Joachim, et al.. (2005). Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. The Breast. 15(2). 219–225. 120 indexed citations
12.
Gelmon, Karen A., John R. Mackey, Shailendra Verma, et al.. (2004). Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories. Clinical Breast Cancer. 5(1). 52–58. 104 indexed citations
13.
Schellens, Jan H.M., Bernhard Heinrich, M. Lehnert, et al.. (2002). Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies. Investigational New Drugs. 20(1). 83–93. 10 indexed citations
14.
Gamucci, Teresa, Bernhard Heinrich, Jan H.M. Schellens, et al.. (2000). Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study. Annals of Oncology. 11(7). 793–797. 20 indexed citations
15.
Heinrich, Bernhard, et al.. (2000). Combined Radiochemotherapy with Docetaxel in Patients with Unresectable Locally Advanced Head and Neck Tumors. Strahlentherapie und Onkologie. 176(2). 67–72. 18 indexed citations
16.
17.
Schilling, T., Bernhard Heinrich, Reinhardt J. Kau, et al.. (1997). Paclitaxel Administered over 3 h Followed by Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Clinical Phase I Study. Oncology. 54(2). 89–95. 15 indexed citations
18.
McLeod, HL, J. Wanders, A Setanoians, et al.. (1996). Multicentre phase II pharmacological evaluation of rhizoxin. British Journal of Cancer. 74(12). 1944–1948. 32 indexed citations
19.
Kaplan, Steven, A.-R. Hanauske, N. Pavlidis, et al.. (1996). Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. British Journal of Cancer. 73(3). 403–405. 20 indexed citations
20.
Schilling, T., Heiner Fiebig, B. R. Winterhalter, et al.. (1996). Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Investigational New Drugs. 14(4). 371–378. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meghan Nechrebecki Breakdown of academic impact, for papers by Neha Luthar Breakdown of academic impact, for papers by Konstantinos Tsaparikos Breakdown of academic impact, for papers by Vincent A. Pollack Breakdown of academic impact, for papers by Elvire Pons‐Tostivint Breakdown of academic impact, for papers by A. D. Colevas Breakdown of academic impact, for papers by Daniel P. Petro Breakdown of academic impact, for papers by Ulla Kasten-Pisula Breakdown of academic impact, for papers by J. Mendelsohn Breakdown of academic impact, for papers by U Vogt
Rankless by CCL
2026